Live news related to CELLECTIS stock (FR0010425595): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The biotech company's stock is among the few showing significant gains this Monday, while the CAC 40 drops by 0.87% during the session. Cellectis has …
Allogene Therapeutics has announced the results of an interim futility analysis of the ALPHA3 pivotal trial evaluating cema-cel, a candidate product d…
Cellectis' flagship program records an intermediate clinical success. The futility analysis of the pivotal ALPHA3 trial, conducted by its partner Allo…
Cellectis is seeing a rebound this Friday, April 10, with its shares trading at €3.158 mid-morning, up more than 4% from the previous day. This recove…
Cellectis, a clinical-stage biotechnology company, presents its 2025 results and an update on its development activities. The company announces the pr…
The biotechnology group Cellectis recorded a 62% increase in its revenue in 2025, driven by its agreements with AstraZeneca and Servier. However, its …
Cellectis stock is up 5.83% at midday this Tuesday, March 10, trading at 3.45 euros compared to 3.26 euros at the previous close. This rebound occurs …
Biotechnology company Cellectis has outlined its strategic focuses for the current year, centered on advancing its allogeneic immunotherapy clinical t…
The stock of French biotech Cellectis recorded a significant increase of 6.89% by midday on Monday, December 29, 2025, reaching 4.42 euros after closi…
Biotechnology company Cellectis announces that the arbitration tribunal has issued its decision in the dispute with Servier. The tribunal has ruled fo…
